Integrated Biopharma Inc (INBP) — SEC Filings
Integrated Biopharma Inc (INBP) — 16 SEC filings. Latest: 8-K (Dec 1, 2025). Includes 6 8-K, 6 10-Q, 2 DEF 14A.
View Integrated Biopharma Inc on SEC EDGAR
Overview
Integrated Biopharma Inc (INBP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: INTEGRATED BIOPHARMA INC (INBP) reported a significant decline in net income for the three months ended September 30, 2025, falling to $123,000 from $259,000 in the prior year, a decrease of 52.5%. Net sales also decreased by 6.8% to $12.689 million from $13.617 million in the same period. Gross pro
Sentiment Summary
Across 16 filings, the sentiment breakdown is: 5 bearish, 11 neutral. The dominant filing sentiment for Integrated Biopharma Inc is neutral.
Filing Type Overview
Integrated Biopharma Inc (INBP) has filed 6 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (16)
Risk Profile
Risk Assessment: Of INBP's 15 recent filings, 3 were flagged as high-risk, 5 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $12.689M |
| Net Income | $123K |
| EPS | $0.00 |
| Debt-to-Equity | 0.25 |
| Cash Position | $4.732M |
| Operating Margin | 1.28% |
| Total Assets | $25.540M |
| Total Debt | $1.208M |
Key Executives
- Christina Kay
- Riva Sheppard
- Eric Friedman
- William H. Milmoe
- Damon DeSantis
- Dean DeSantis
- Robert Canarick
- Dina L. Masi
Industry Context
Integrated Biopharma operates within the highly competitive pharmaceutical services sector, encompassing contract manufacturing, warehousing, distribution, and raw material supply. This industry is characterized by significant R&D investment, stringent regulatory requirements, and evolving market demands for specialized services. Companies often face pressure on pricing and margins due to the presence of numerous players and the need for continuous technological upgrades.
Top Tags
financials (4) · financial-reporting (3) · Nutraceuticals (2) · Contract Manufacturing (2) · Small Cap (2) · 10-Q (2) · 8-k (2) · operations (2) · Biopharma (1) · Earnings Decline (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales | $12.689M | Decreased by 6.8% from $13.617M in Q3 2024 |
| Net Income | $123K | Decreased by 52.5% from $259K in Q3 2024 |
| Gross Profit | $1.019M | Decreased by 25.7% from $1.371M in Q3 2024 |
| Operating Income | $163K | Decreased by 66.7% from $490K in Q3 2024 |
| Cash at End of Period | $4.732M | Increased from $3.615M at June 30, 2025 |
| Net Cash Provided by Operating Activities | $1.301M | Increased from $657K in Q3 2024 |
| Common Shares Outstanding | 31,059,610 | As of November 10, 2025 |
| Basic Net Income Per Common Share | $0.00 | Decreased from $0.01 in Q3 2024 |
| Shares of Common Stock outstanding | 31,059,610 | Entitled to vote as of Record Date October 17, 2025 |
| Beneficial ownership by William H. Milmoe | 42.5% | Significant insider control over voting matters |
| Beneficial ownership by Dean DeSantis | 41.2% | Significant insider control over voting matters |
| Beneficial ownership by Directors and executive officers as a group | 67.4% | Collective insider control over voting matters |
| Date of Annual Meeting | December 1, 2025 | Key date for stockholder decisions |
| Record Date | October 17, 2025 | Date for determining eligible voters |
| Term for Class III director | 3 years | Duration of elected director's service |
Forward-Looking Statements
- {"claim":"Integrated BioPharma Inc. will continue to report net losses in the near term.","entity":"Integrated BioPharma Inc.","targetDate":"June 30, 2024","confidence":"high"}
- {"claim":"The company's stock price will likely remain under pressure due to ongoing financial losses.","entity":"Integrated BioPharma Inc.","targetDate":"June 30, 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Integrated Biopharma Inc (INBP)?
Integrated Biopharma Inc has 16 recent SEC filings from Feb 2024 to Dec 2025, including 6 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INBP filings?
Across 16 filings, the sentiment breakdown is: 5 bearish, 11 neutral. The dominant sentiment is neutral.
Where can I find Integrated Biopharma Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Integrated Biopharma Inc (INBP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Integrated Biopharma Inc?
Key financial highlights from Integrated Biopharma Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for INBP?
The investment thesis for INBP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Integrated Biopharma Inc?
Key executives identified across Integrated Biopharma Inc's filings include Christina Kay, Riva Sheppard, Eric Friedman, William H. Milmoe, Damon DeSantis and 3 others.
What are the main risk factors for Integrated Biopharma Inc stock?
Of INBP's 15 assessed filings, 3 were flagged high-risk, 5 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Integrated Biopharma Inc?
Recent forward-looking statements from Integrated Biopharma Inc include guidance on {"claim":"Integrated BioPharma Inc. will continue to report net losses in the near term.","entity":"Integrated BioPharma and 1 other predictions.